Equity Research firms currently have a positive stance on shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 2.30. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $212.84 on a short term basis.
At the time of writing, the stock was trading at $152.65. This represents a change from the opening price of -6.17%. In terms of performance, year to date, the stock is 8.72%. The monthly stock performance comes in at 10.60%. For the quarter, shares are performing at 13.18%. Weekly performance analysis shows the equity at -2.19%.
In taking a look at technical levels, shares are trading -4.89% away from the 50 day simple moving average and 7.65% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -29.97% away from it’s 52- week high and 70.06% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Intercept Pharmaceuticals, Inc.’s RSI stands at 42.86. In looking at volatility levels, the shares saw weekly volatility of 4.59% and 3.90% over the past month.